Monoclonal antibody therapy for lymphoma

Campbell, Peter; Marcus, Robert

doi:10.1016/s0268-960x(03)00005-5

Cited by 33 publications

(23 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, progression-free survival was short and similar in patients who achieved complete molecular response and those who did not (16.5 vs. 18.8 months, p = 0.51) [23]. Other targeted and experimental therapies with Y-90 ibritumomab tiuxetan, 131 I-tositumomab [24], bortezomib [25, 26], and their combination show response rates of up to 80%, but no survival advantage has been proven yet. Aggressive induction therapy regimens followed by hematopoietic cell transplantation have shown promising results in some patients, with a 3-year event-free survival and overall survival of 72 and 92%, respectively [27].…”

Section: Discussionmentioning

confidence: 99%

Chronic Paraneoplastic Cutaneous Syndrome Preceding an Indolent Variant of Mantle Cell Lymphoma: Favorable Response to Rituximab

Nemets¹,

Ronen

Lugassy³

2006

Acta Haematol

View full text Add to dashboard Cite

Mantle cell lymphoma (MCL) is an aggressive type of malignant lymphoma with short median survival despite conventional therapy. We describe the unusual case of a 66-year-old man with a chronic skin rash which preceded the occurrence of an indolent MCL by 2 years. Repeated skin biopsies did not show involvement by the lymphoma. Short therapy with rituximab resulted in the complete and lasting resolution of the cutaneous lesions.

show abstract

Section: Discussionmentioning

confidence: 99%

Chronic Paraneoplastic Cutaneous Syndrome Preceding an Indolent Variant of Mantle Cell Lymphoma: Favorable Response to Rituximab

Nemets¹,

Ronen

Lugassy³

2006

Acta Haematol

View full text Add to dashboard Cite

show abstract

“…It is easier and more economical to develop monoclonal antibodies than to engineer patient-specific anti-idiotype antibody (Campbell & Marcus, 2003). A number of phase I and II clinical trials are incorporating radioconjugates to exploit their 'crossfire effect' against the radiosensitive myeloma cells.…”

Section: Future Directionsmentioning

confidence: 99%

“…The initial success of rituximab in indolent follicular lymphomas was followed by positive results in diffuse large cell lymphoma. The R-CHOP regimen (rituximab, cyclophosphamide, adriamycin, oncovin, prednisolone) has now become the treatment of choice for most cases of diffuse large cell lymphoma (Coiffier et al, 2002;Campbell & Marcus, 2003;Feugier et al, 2005). Marked interest has also been generated by the objective response seen with this mAb in Waldenstrom Macroglobulinemia (WM; Dimopoulos et al, 2002;Gertz et al, 2004).…”

mentioning

confidence: 99%

Anti‐CD20 monoclonal antibody therapy in multiple myeloma

et al. 2008

View full text Add to dashboard Cite

SummaryCD20 is a particularly appealing target that is expressed on the surface of almost all B cells, with no significant shedding, secretion or internalization. In contrast to the demonstrated efficacy of anti-CD20 strategies in various B-cell lymphoproliferative disorders, the role of such therapy in multiple myeloma is undetermined and controversial. The expression of CD20 by myeloma cells is heterogeneous, and can be detected only in 13-22% of patients. However, there is increasing interest in testing anti-CD20 therapy in myeloma because of recent studies suggesting the existence of clonogenic CD20-positive precursor B cells in the disease. This article reviews the rationale, preclinical and clinical activity of anti-CD20 therapy in myeloma. Clinical trials show that anti-CD20 therapy with rituximab elicits a partial response in approximately 10% of CD20 + patients with multiple myeloma. In addition, there is preliminary evidence of disease stabilization in 50-57% of CD20 + patients for a period of 10-27 months. Further largescale clinical trials are therefore needed to establish the role of this promising strategy in the treatment of myeloma.

show abstract

“…In spite of recent progress in MCL treatment, the disease prognosis remains poor mainly due to the intrinsic resistance of malignant cells to conventional chemotherapy (37)(38)(39), and virtually, all patients, even those who exhibit complete response, will relapse. Because CD20 antigen is expressed in the majority of non-Hodgkin's lymphomas, including MCL, immunotherapy with anti-CD20 antibodies (rituximab) have been used (40,41).…”

Section: Discussionmentioning

confidence: 99%

Prevention of Mantle Lymphoma Tumor Establishment by Routing Transferrin Receptor toward Lysosomal Compartments

et al. 2007

View full text Add to dashboard Cite

Mantle cell lymphoma (MCL) is one of the most frequent of the newly recognized non-Hodgkin's lymphomas. The major problem of MCL therapy is the occurrence of relapse and subsequent resistance to chemotherapy and immunotherapy in virtually all cases. Here, we show that one injection of antihuman transferrin receptor (TfR) monoclonal antibody A24 totally prevented xenografted MCL tumor establishment in nude mice. It also delayed and inhibited tumor progression of established tumors, prolonging mice survival. In vitro, A24 induced up to 85% reduction of MCL cell proliferation (IC 50 = 3.75 nmol/L) independently of antibody aggregation, complement-dependent or antibody-dependent cell-mediated cytotoxicity. A24 induced MCL cell apoptosis through caspase-3 and caspase-9 activation, either alone or synergistically with chemotherapeutic agents. A24 induced TfR endocytosis via the clathrin adaptor protein-2 complex pathway followed by transport to lysosomal compartments. Therefore, A24-based therapies alone or in association with classic chemotherapies could provide a new alternative strategy against MCL, particularly in relapsing cases. [Cancer Res 2007;67(3):1145-54]

show abstract

Monoclonal antibody therapy for lymphoma

Cited by 33 publications

References 58 publications

Chronic Paraneoplastic Cutaneous Syndrome Preceding an Indolent Variant of Mantle Cell Lymphoma: Favorable Response to Rituximab

Chronic Paraneoplastic Cutaneous Syndrome Preceding an Indolent Variant of Mantle Cell Lymphoma: Favorable Response to Rituximab

Anti‐CD20 monoclonal antibody therapy in multiple myeloma

Prevention of Mantle Lymphoma Tumor Establishment by Routing Transferrin Receptor toward Lysosomal Compartments

Contact Info

Product

Resources

About